MBX Biosciences has raised $216 million across three funding rounds, supported by leading biotech investors including Frazier Healthcare Partners, Orbimed, Wellington, RA Capital Management, Deep Track Capital, and others. The company’s funding history includes a Series A of $34.6M, Series B of $115M, and a Series C of $63.5M, backing its mission to develop precision therapies for rare endocrine disorders. With strong investor confidence and a focused drug development pipeline, MBX Biosciences continues to expand clinical programs and strengthen its leadership in endocrine therapeutics.